Brief: Inventiva Announces Positive Results From Phase II Legend Study

Inventiva SA

19/03/2024 06:25

March 19 (Reuters) - Inventiva SA  IVAA.PA :
    * INVENTIVA ANNOUNCES POSITIVE RESULTS FROM THE PHASE II,
LEGEND,
PROOF-OF-CONCEPT STUDY COMBINING LANIFIBRANOR WITH EMPAGLIFLOZIN
IN PATIENTS WITH MASH/NASH AND T2D
    * THE LEGEND TRIAL HAS BEEN DESIGNED AS A MULTI-CENTER,
RANDOMIZED, 24-WEEK TREATMENT, PLACEBO-CONTROLLED PHASE II
PROOF-OF-CONCEPT TRIAL TO ASSESS THE SAFETY AND EFFICACY OF
LANIFIBRANOR IN COMBINATION WITH THE SGLT2 INHIBITOR
EMPAGLIFLOZIN FOR THE TREATMENT OF PATIENTS WITH NON-CIRRHOTIC
MASH/NASH AND T2
    * THE STUDY ALSO DEMONSTRATED A STATISTICALLY SIGNIFICANT
REDUCTION IN HEPATIC STEATOSIS MEASURED BY MRI-PDFF1, IN
PATIENTS TREATED WITH LANIFIBRANOR ALONE AND IN COMBINATION WITH
EMPAGLIFLOZIN, -47% AND -38% RESPECTIVELY, COMPARED TO PLACEBO
(0%)
    * 83% AND 67% OF PATIENTS TREATED WITH LANIFIBRANOR ALONE OR
IN
COMBINATION WITH EMPAGLIFLOZIN RESPECTIVELY, SHOWED A REDUCTION
GREATER OR EQUAL TO 30% OF THEIR HEPATIC FAT, COMPARED TO 0% IN
THE PLACEBO ARM

Source text for Eikon:  ID:nGNE4YV4kK 
Further company coverage:  IVAA.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))